80 related articles for article (PubMed ID: 14583876)
21. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
22. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Hedlin P; Blondeau JM
Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
[TBL] [Abstract][Full Text] [Related]
23. Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method.
Ngan CC; Lim T; Choo CM; Toh GL; Lim YS
Diagn Microbiol Infect Dis; 2004 Mar; 48(3):207-10. PubMed ID: 15023431
[TBL] [Abstract][Full Text] [Related]
24. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.
Callegan MC; Ramirez R; Kane ST; Cochran DC; Jensen H
Adv Ther; 2003; 20(5):246-52. PubMed ID: 14964344
[TBL] [Abstract][Full Text] [Related]
25. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections.
Ozdek SC; Miller D; Flynn PM; Flynn HW
Ocul Immunol Inflamm; 2006 Dec; 14(6):347-51. PubMed ID: 17162605
[TBL] [Abstract][Full Text] [Related]
26. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
27. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
[TBL] [Abstract][Full Text] [Related]
28. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
[TBL] [Abstract][Full Text] [Related]
29. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Alou L; Giménez MJ; Sevillano D; Aguilar L; Cafini F; Echeverría O; Pérez-Trallero E; Prieto J
J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
[TBL] [Abstract][Full Text] [Related]
30. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.
Metzler K; Hansen GM; Hedlin P; Harding E; Drlica K; Blondeau JM
Int J Antimicrob Agents; 2004 Aug; 24(2):161-7. PubMed ID: 15288315
[TBL] [Abstract][Full Text] [Related]
31. Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system.
Isaeva Y; Bukatina A; Krylova L; Nosova E; Makarova M; Moroz A
J Antimicrob Chemother; 2013 Oct; 68(10):2274-81. PubMed ID: 23788475
[TBL] [Abstract][Full Text] [Related]
32. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates.
Miller D; Flynn PM; Scott IU; Alfonso EC; Flynn HW
Arch Ophthalmol; 2006 Apr; 124(4):479-83. PubMed ID: 16606872
[TBL] [Abstract][Full Text] [Related]
33. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Segreti J; Jones RN; Bertino JS
J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
[TBL] [Abstract][Full Text] [Related]
34. In vitro antibacterial activity of fluoroquinolones against Porphyromonas gingivalis strains.
Eick S; Schmitt A; Sachse S; Schmidt KH; Pfister W
J Antimicrob Chemother; 2004 Aug; 54(2):553-6. PubMed ID: 15231772
[TBL] [Abstract][Full Text] [Related]
35. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
37. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
38. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Park SH; Lim JA; Choi JS; Kim KA; Joo CK
Cornea; 2009 Jan; 28(1):68-72. PubMed ID: 19092409
[TBL] [Abstract][Full Text] [Related]
39. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
40. Concentrations of moxifloxacin in serum and synovial fluid, and ex vivo bactericidal activity against arthritis-causing pathogens.
Dan M; Keynan O; Feldbrin Z; Poch F
Diagn Microbiol Infect Dis; 2004 Apr; 48(4):283-6. PubMed ID: 15062922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
